Circulating tumor DNA determinants of response and outcome in relapsed/refractory mantle cell lymphoma.

ABSTRACT:

Abstract

Clinical tools to guide treatment decisions in relapsed/refractory mantle cell lymphoma (R/R MCL) are limited. Moreover, the translational potential of circulating tumor DNA (ctDNA) remains largely unproven. We designed and applied panel-based duplex sequencing of ctDNA to study molecular determinants of response and outcome in 58 patients with R/R MCL treated with venetoclax, lenalidomide, and rituximab. Genetic analysis revealed molecular predictors of response that were independent of clinical prognostic factors, with SMARCA4-mutated R/R MCLs responding to therapy, whereas TP53 mutations conferred resistance. Pretreatment ctDNA captured spatial heterogeneity, and its concentration was associated with multiple clinicopathological disease features and survival, independen

SUBMITTER: Meriranta L 

PROVIDER: S-EPMC12447437 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature